Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

(2012) Akira Fukutomi et al.   INVESTIGATIONAL NEW DRUGS

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors

(2012) M. C. Heinrich et al.   MOLECULAR CANCER THERAPEUTICS

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates

(2011) AM Filppula et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

(2011) Paul Hamberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

(2011) Sachi Morita et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

(2011) J. Drappatz et al.   JOURNAL OF NEURO-ONCOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors

(2009) T. Muhlenberg et al.   CANCER RESEARCH

High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model

(2009) G. Floris et al.   CLINICAL CANCER RESEARCH

Just Enough Palliation: Radiation Dose and Outcome in Patients With Non–Small-Cell Lung Cancer

(2008) Henry Wagner   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY